Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

Conditions

• Recurrent Nervous System Lymphoma
• Recurrent Primary Vitreoretinal DLBCL
• Refractory Nervous System Lymphoma
• Refractory Primary Vitreoretinal DLBCL

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Nivolumab — BIOLOGICAL
  Given IV
• Pomalidomide — DRUG
  Given PO

Study Details

This phase I trials studies side effects and best dose of pomalidomide when given together with nivolumab in treating patients with primary central nervous system diffuse large B cell lymphoma or primary vitreoretinal diffuse large B cell lymphoma that has come back or that has not responded to treatment. Immunotherapy with monoclonal antibodies, such as pomalidomide and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Key Dates

Start date

Jan 30, 2019

Status verified

Sep 2021

Primary completion

Dec 30, 2020

Completion

Sep 15, 2021

Study Design

Enrollment

3 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (nivolumab and pomalidomide)
  Patients receive nivolumab IV over 30 minutes on day 1 and pomalidomide PO on days 1-14. Treatment repeats every 4 weeks until disease progression or unacceptable toxicity.

Primary Outcome Measure

Maximum-tolerated dose (MTD) of pomalidomide [ Time Frame: Up to 28 days ]

Locations (2)

Find similar trials in Jacksonville, FL